Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ARTiDe

Financiado

Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes...

Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, and high social burden. It is caused by the autoimmune destruction of insulin-producing bet... ver más

30/06/2028

INSERM

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-27

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs

I+D

Cerrada hace 2 años

0% 100%

11 Participantes

INSERM

2.47M€ | Lider

MILTENYI BIOTEC BV CO KG

1.52M€ | Participante

ILTOO PHARMA

176.25K€ | Participante

Proyectos interesantes

SAF2016-77227-R LINFOCITOS T Y B ANTI-PERIFERINA Y ANTI-CROMOGRANINA T AND B... 169K€ Cerrado

RTI2018-097414-B-I00 MECANISMOS DE TOLERANCIA EN LA DIABETES DE TIPO 1: PROCESAMI... 182K€ Cerrado

SAF2012-35344 DE LOS ANTIGENOS AL TCR. UNA APROXIMACION SISTEMATICA A LA R... 291K€ Cerrado

SAF2011-23317 EL PAPEL DE LA AUTOFAGIA CELULAR EN LA TOLERANCIA CENTRAL Y... 169K€ Cerrado

PID2021-123083NB-I00 ESTUDIO DEL MECANISMO DE TRANSREGENERACION ACTIVADO POR EL S... 266K€ Cerrado

SAF2010-21977 EFECTO DE LAS CITOQUINAS PROINFLAMATORIAS SOBRE LA CAPACIDAD... 18K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 62 meses Fecha Inicio: 2023-04-27
Fecha Fin: 2028-06-30

Presupuesto del proyecto 7M€

Descripción del proyecto Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, and high social burden. It is caused by the autoimmune destruction of insulin-producing beta cells, yet the standard of care is insulin replacement, acting only at the symptom level. Thus, T1D is a disease with a high unmet need for innovative therapy. Ideally, such therapy shall suppress selectively the immune cells driving T1D without impairing protective immunity. Regulatory T cells (Tregs) are the guardians of human immune tolerance, and genetic defects in Tregs are associated with T1D. Tregs additionally possess tissue regenerative capacity, making them ideal to treat T1D in cell therapy. However, such therapy, performed with polyclonally expanded patient Tregs, showed limited efficacy in T1D. These expanded Tregs are however poor in relevant autoreactive Tregs to save insulin-producing cells. In fact, the identification and manufacturing of autoreactive Tregs remain fundamental technical challenges to successfully apply these cells in the clinic. ARTiDe aims at a breakthrough in antigen-specific Treg therapy in T1D by establishing the production of human Tregs genetically engineered to express an autoreactive T cell antigen receptor (TCR) ready for clinical use. To achieve this ambitious goal, ARTiDe combines the complementary expertise of 8 partners providing novel technologies for the systematic identification of autoantigen-specific Tregs in humans, the selection of optimal TCR to produce protective Tregs, and innovative humanized T1D pre-clinical models to test their efficacy and safety, as well as Treg supporting strategies, in vivo. World-leading biotechs for adoptive T cell therapy will establish novel GMP-compatible manufacturing of highly purified TCR-engineered Tregs. ARTiDe will deliver a Treg production process and regulatory certificates that will allow launching a phase 1 clinical trial just after the project.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores